scholarly journals Identification of traumatic acid as a potential plasma biomarker for sarcopenia using a metabolomics‐based approach

2021 ◽  
Author(s):  
Jaw‐Shiun Tsai ◽  
San‐Yuan Wang ◽  
Chin‐Hao Chang ◽  
Chin‐Ying Chen ◽  
Chiung‐Jung Wen ◽  
...  
Keyword(s):  
Plasma Biomarker ◽  
Traumatic Acid

cis-Traumatic Acid and Related Compounds

1945 ◽  
Vol 67 (7) ◽  
pp. 1171-1175 ◽  
Author(s):  
Walter M. Lauer ◽  
Walter J. Gensler
Keyword(s):  
Traumatic Acid ◽  
Related Compounds

scholarly journals Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy

2011 ◽  
Vol 54 (5) ◽  
pp. 393-402 ◽  
Author(s):  
ShuLong Li ◽  
Xin Liu ◽  
Lai Wei ◽  
HuiFen Wang ◽  
JiYang Zhang ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Plasma Biomarker

TNFRSF11B: A potential plasma biomarker for diagnosis of obstructive sleep apnea

2019 ◽  
Vol 490 ◽  
pp. 39-45 ◽  
Author(s):  
Wan-Wan Wen ◽  
Yu Ning ◽  
Qing Zhang ◽  
Yun-Xiao Yang ◽  
Yi-Fan Jia ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Plasma Biomarker ◽  
Obstructive Sleep

scholarly journals Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Michiko Takakura ◽  
Akira Yokomizo ◽  
Yoshinori Tanaka ◽  
Michimoto Kobayashi ◽  
Giman Jung ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Carbonic Anhydrase ◽  
Cancer Patients ◽  
Plasma Proteins ◽  
Specific Antigen ◽  
Healthy Controls ◽  
Gray Zone ◽  
Plasma Biomarker ◽  
Carbonic Anhydrase I ◽  
Discrimination Rate

Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40,678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (, Mann-Whitney test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level.

scholarly journals Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles

2014 ◽  
Vol 211 (4) ◽  
pp. 380.e1-380.e13 ◽  
Author(s):  
Kok Hian Tan ◽  
Soon Sim Tan ◽  
Siu Kwan Sze ◽  
Wai Kheong Ryan Lee ◽  
Mor Jack Ng ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Biomarker Discovery ◽  
Plasma Biomarker

scholarly journals Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Maryam Ebadi ◽  
Vera C. Mazurak
Keyword(s):  
Adipose Tissue ◽  
Plasma Levels ◽  
Cancer Cachexia ◽  
Prognostic Biomarker ◽  
Prognostic Biomarkers ◽  
Plasma Biomarker ◽  
Fat Loss ◽  
Early Detection And Prevention ◽  
Potential Biomarkers

Fat loss is associated with shorter survival and reduced quality of life in cancer patients. Effective intervention for fat loss in cachexia requires identification of the condition using prognostic biomarkers for early detection and prevention of further depletion. No biomarkers of fat mass alterations have been defined for application to the neoplastic state. Several inflammatory cytokines have been implicated in mediating fat loss associated with cachexia; however, plasma levels may not relate to adipose atrophy. Zinc-α2-glycoprotein may be a local catabolic mediator within adipose tissue rather than serving as a plasma biomarker of fat loss. Plasma glycerol and leptin associate with adipose tissue atrophy and mass, respectively; however, no study has evaluated their potential as a prognostic biomarker of cachexia-associated fat loss. This review confirms the need for further studies to identify valid prognostic biomarkers to identify loss of fat based on changes in plasma levels of biomarkers.

Sign in / Sign up

Export Citation Format

Share Document